Simplify Logo

Full-Time

Director – Medical Affairs

Posted on 4/5/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Hardware
Biotechnology
Healthcare

Expert

Boston, MA, USA

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Advanced degree in a scientific or clinical field (e.g., M.D., Ph.D., Pharm.D., MSN)
  • 10+ years of pharmaceutical/biotechnology industry experience
  • Experience delivering Medical Education strategies and programs
  • Experience with publications and scientific communications planning and execution
  • Adept at scientific congress strategic planning and execution
  • Broad experience in medical affairs
  • Ability to build relationships with internal cross-functional partners and oversee third-party vendors
  • Excellent written and verbal communication skills
  • High integrity and sense of urgency
  • Available for domestic and international travel up to 10%
  • Experience with patient advocacy and government affairs work is a plus
  • Experience in cardiovascular disease is a plus
  • Experience with emergent and innovative technology is a plus
Responsibilities
  • Support the establishment of the Medical Affairs function at Verve
  • Develop and execute scientific communication plans for Verve programs
  • Oversee medical education strategy
  • Provide scientific and technical input on clinical and scientific data
  • Disseminate clinical information to key stakeholders
  • Collaborate in the development of KOL engagement strategies
  • Support clinical trial activities
  • Execute real-world evidence data generation and health economics outcomes research
  • Ensure scientific accuracy and compliance
  • Travel internationally and domestically up to 10%
  • Other duties as assigned

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

7%

1 year growth

5%

2 year growth

54%
INACTIVE